Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea

폐경기 골다공증 환자에서 데노수맙 사용에 대한 비용-효과 분석

  • Bae, Green (College of Pharmacy, Ewha Womans University) ;
  • Kwon, Hye-Young (Division of Biology & Public Health, Mokwon University)
  • 배그린 (이화여자대학교 약학대학) ;
  • 권혜영 (목원대학교 의생명보건학부)
  • Received : 2018.02.20
  • Accepted : 2018.06.16
  • Published : 2018.06.29
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In South Korea, 22.3% of women ${\geq}50years$ of age and 37% of women ${\geq}70years$ of age visit the doctor to obtain treatment for osteoporosis. According to the analysis of the National Health Insurance Services claim data between 2008 and 2012, the number and incidence of hip and vertebral fractures increased during the same period. Denosumab, a newly marketed medicine in Korea, is the first RANK inhibitor. Methods: A cost-utility analysis was conducted from a societal perspective to prove the superiority of denosumab to alendronate. A Markov cohort model was used to investigate the cost-effectiveness of denosumab. A 6-month cycle length was used in the model, and all patients were individually followed up through the model, from their age at treatment initiation to their time of death or until 100 years of age. The model consisted of eight health states: well; hip fracture; vertebral fracture; wrist fracture; other osteoporotic fracture; post-hip fracture; post-vertebral fracture; and dead. All patients began in the well-health state. In this model, 5% discounted rate, two-year maximum offset time, and persistence were adopted. Results: The total lifetime costs for alendronate and denosumab were USD 5,587 and USD 6,534, respectively. The incremental cost-effectiveness ratio (ICER) for denosumab versus alendronate was USD 20,600/QALY. Given the ICER threshold in Korea, the results indicated that denosumab was remarkably superior to alendronate. Conclusion: Denosumab is a cost-effective alternative to the oral anti-osteoporotic treatment, alendronate, in South Korea.

Keywords

References

  1. Cooper C, Campion G, Melton Lr. Hip fractures in the elderly: a worldwide projection. Osteoporos Int 1992;2(6):285-9. https://doi.org/10.1007/BF01623184
  2. Ha YC. Epidemiology and Economic Burden of Osteoporosis in South Korea. J Korean Fract Soc 2011;24(1).
  3. Ahn JH, Hyun MK, Park SY, et al. Development of reasonable Korean evaluation criteria for osteoporosis. NECA 2011:1-295.
  4. Park HM. Current use of drugs for osteoporosis in Korea. Korean J Obstet 2010;53(2).
  5. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clinic Endocrinol Metab 2005;90(3):1294-01. https://doi.org/10.1210/jc.2004-0952
  6. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surge Oral Med Oral Pathol Oral radiol Endod 2006;102(4):433-41. https://doi.org/10.1016/j.tripleo.2006.06.004
  7. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006;21(10):1503-05. https://doi.org/10.1359/jbmr.060712
  8. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009;140(1):61-6. https://doi.org/10.14219/jada.archive.2009.0019
  9. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358(12):1304-06. https://doi.org/10.1056/NEJMc0707493
  10. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(1):89-90. https://doi.org/10.1056/NEJMc0808738
  11. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65. https://doi.org/10.1056/NEJMoa0809493
  12. Jang JS. Osteoporotic Fracture-Medical Treatment. J Korean Fract Soc 2010;23(3):326-40. https://doi.org/10.12671/jkfs.2010.23.3.326
  13. Service HIRA. [Pharmaceutical] Notification No. 2017-180 Information on the criteria of health care service reimbursement. In: standards Pb, ed. Wonju 2017.
  14. Strom O, Borgstrom F, Sen S, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18(8):1047-61. https://doi.org/10.1007/s00198-007-0349-5
  15. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 2007;18(1):9-23. https://doi.org/10.1007/s00198-006-0257-0
  16. Jang SM, Park CM, Jang SH, et al. A study on the medical utilization and prescription pattern of osteoporosis. Health Insurance Review and Assessment; 2009.
  17. Lee YK, Jang S, Lee H, et al. Mortality after vertebral fracture in Korea. Osteoporos Int 2012;23(7):1859-65. https://doi.org/10.1007/s00198-011-1833-5
  18. Yoon HK, Park C, Jang S, et al. Incidence and mortality following hip fracture in Korea. J Korean Med 2011; 26(8):1087-92. https://doi.org/10.3346/jkms.2011.26.8.1087
  19. Barrett JA, Baron JA, Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Inte 2003;14(11):889-94. https://doi.org/10.1007/s00198-003-1494-0
  20. Kanis J, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12(5):417-27. https://doi.org/10.1007/s001980170112
  21. Peasgood T, Herrmann K, Kanis J, et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009;20(6):853. https://doi.org/10.1007/s00198-009-0844-y
  22. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15(2):108-12. https://doi.org/10.1007/s00198-003-1516-y
  23. Borgström F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporosi Int 2006;17(5):637-50. https://doi.org/10.1007/s00198-005-0015-8
  24. Oleksik A, Lips P, Dawson A, et al. Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral Fractures. J Bone Miner Res 2000;15(7):1384-92. https://doi.org/10.1359/jbmr.2000.15.7.1384
  25. Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24(1):209-17. https://doi.org/10.1007/s00198-012-2068-9
  26. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. JCEM 2011;96(4):972-80.
  27. Curtis LA. Unit costs of health and social care 2008, ed. Personak Social services research unit, 2008.
  28. Jonsson E, Cheng L, Strom O, et al. Systematic Review and Meta-Analysis of Persistence With Denosumab in Patients With Osteoporosis. Value in Health 2014;17(7):A383-4.
  29. Li L, Roddam A, Gitlin M, et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 2012;19(1):33-40. https://doi.org/10.1097/gme.0b013e318221bacd
  30. Zethraeus N, Strom O, Borgstrom F. What is the risk of institutionalization after hip fracture? Paper presented at: Osteoporosis International 2006.
  31. Si L, Winzenberg T, de Graaff B, et al. A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int 2014;25(8):1987-97. https://doi.org/10.1007/s00198-014-2636-2